1. Reversal of diabetes-induced depletion of bone marrow (BM)–resident LSK cells and impairment of proliferation by ANG-(1-7) treatment.
Reversal of diabetes-induced depletion of bone marrow (BM)–resident LSK cells and impairment of proliferation by ANG-(1-7) treatment. A and B: The number of BM LSK cells was decreased in STZ-diabetic or db/db mice, which was reversed by ANG-(1-7) treatment (n = 6–8). C and D: The proliferation of cells was determined using a BrdU proliferation assay kit (Roche Bioscience) by using 10,000 cells/well in RPMI 1640 medium for 48 h with or without drug treatments. Proliferation was expressed as a fold increase relative to the effect of mitomycin (1 μmol/L), an inhibitor of proliferation. LSK cells derived from STZ or db/db mice showed decreased proliferation in basal conditions or in response to SDF or VEGF. Proliferation was restored to normal in cells derived from ANG-(1-7)–treated diabetic mice (n = 6). WBCs, white blood cells.
Goutham Vasam et al. Diabetes 2017;66:
©2017 by American Diabetes Association